Plasma Transfusion in Liver Transplantation
Plasma Transfusion in Liver Transplantation : a Randomized, Double Blind, Multicenter Trial of Methylene Blue, Solvent/Detergent and Quarantined Plasma.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Three types of plasma are transfused in bleeding patients undergoing liver transplantation:
- quarantined plasma,
- methylene blue treated plasma,
- solvent/detergent plasma. The main purpose is to show that the volume of methylene blue treated plasma consumed intraoperatively is equivalent to that of the 2 other types of plasma.
In addition, the correction of coagulation abnormalities are studied.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- EFS
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age 18 yo and above
- consent is signed,
- liver transplantation is indicated,
- plasma is transfused
Exclusion Criteria:
- multiorgan transplantation (except combined kidney and liver transplantation)
- allergy to methylene blue.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Quarantined FFP
|
transfusion of more than 15 mL/Kg of plasma
|
|
Active Comparator: Methylene blue FFP
|
transfusion of more than 15 mL/Kg of plasma
|
|
Active Comparator: Solvent detergent FFP
|
transfusion of more than 15 mL/Kg of plasma
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Volume of transfused plasma during surgery
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
correction of coagulation abnormalities
Time Frame: 5 years
|
5 years
|
|
immediate and delayed adverse events
Time Frame: 15 days
|
15 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yves Ozier, MD, PhD, Hôpital Cochin, Paris, France
- Principal Investigator: Emmanuel Samain, MD, PhD, hôpital Jean Minjoz, Besançon, France
- Principal Investigator: Marie - Christine Gillon, MD, Hôpital Paul Brousse, Villejuif, France
- Principal Investigator: Loïc Villalon, MD, Hôpital Pontchaillou
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EFS plasma trial
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.